The obesity epidemic has led to an increased incidence of nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. AMP-activated protein kinase (Ampk) regulates energy homeostasis and is activated by cellular stress, hormones and the widely prescribed type 2 diabetes drug metformin 1,2 . Ampk phosphorylates mouse acetyl-CoA carboxylase 1 (Acc1; refs. 3,4) at Ser79 and Acc2 at Ser212, inhibiting the conversion of acetyl-CoA to malonyl-CoA. The latter metabolite is a precursor in fatty acid synthesis 5 and an allosteric inhibitor of fatty acid transport into mitochondria for oxidation 6 . To test the physiological impact of these phosphorylation events, we generated mice with alanine knock-in mutations in both Acc1 (at Ser79) and Acc2 (at Ser212) (Acc double knock-in, AccDKI). Compared to wild-type mice, these mice have elevated lipogenesis and lower fatty acid oxidation, which contribute to the progression of insulin resistance, glucose intolerance and NAFLD, but not obesity. Notably, AccDKI mice made obese by high-fat feeding are refractory to the lipid-lowering and insulin-sensitizing effects of metformin. These findings establish that inhibitory phosphorylation of Acc by Ampk is essential for the control of lipid metabolism and, in the setting of obesity, for metformin-induced improvements in insulin action.
Genetic disruption of Acc1 (refs. 7,8) or Acc2 (refs. 9-12) has yielded conflicting results as to the role of these enzymes in controlling fatty acid metabolism. The Ampk-mediated phosphorylation of Acc1 at Ser79 (Acc1 Ser79, equivalent to Acc2 Ser212) inhibits catalytic activity in cell-free systems 13 . To test the importance of Ampk signaling to Acc in vivo, we generated Acc1-S79A and Acc2-S212A knock-in mice and intercrossed these strains to generate AccDKI mice ( Supplementary Fig. 1a,b) . We examined Ampkmediated phosphorylation of liver Acc1 Ser79 and Acc2 Ser212 by mass spectrometry and confirmed the absence of phosphorylation at these sites in the AccDKI but not the wild-type (WT) mice ( Fig. 1a and Supplementary Fig. 1c ). We observed no change in baseline Ampk Thr172 phosphorylation in livers from all three lines and no change in the expression of either Acc isoform (Fig. 1a) . The activities of Acc1 and Acc2 were elevated in AccDKI mice (Fig. 1b,c) compared to WT controls, consistent with Ampk phosphorylation negatively regulating Acc1 and Acc2 enzyme activity in vivo. Furthermore, dephosphorylation of liver Acc1 using lambda phosphatase increased enzyme activity in liver from WT but not AccDKI mice ( Supplementary Fig. 2a ), indicating that Ser79 is the main regulatory site for Acc1 activity. Both WT and AccDKI enzymes remained sensitive to citrate activation, confirming that other mechanisms of Acc regulation remained intact in the AccDKI livers.
Liver malonyl-CoA content is dependent on Acc activity for synthesis and on malonyl-CoA decarboxylase activity for degradation. AccDKI mice had elevated liver malonyl-CoA in the fed state compared to WT control mice (Fig. 1d) , but this did not result in compensatory upregulation of malonyl-CoA decarboxylase transcript level (Supplementary Fig. 2b ). Hepatocytes from AccDKI mice had higher de novo lipogenesis (Fig. 1e) and lower fatty acid oxidation (Fig. 1f) compared to those from WT controls. Consistent with this, AccDKI mice also had higher hepatic de novo lipogenesis in vivo ( Supplementary Fig. 2c ) than WT mice. In contrast, single mutations in Acc1 or Acc2 had minimal changes in these parameters, indicating redundancy between Acc isoforms ( Supplementary Fig. 2d-f) , which is consistent with a previous siRNA knockdown study 14 .
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin Skeletal muscle is the major tissue contributing to the basal metabolic rate, and Acc2 and malonyl-CoA have been shown to be important in regulating skeletal muscle fatty acid oxidation in some 9, 11 but not all 10,12 studies. We found that relative to WT controls, malonyl-CoA was higher in skeletal muscle of AccDKI mice (Supplementary Fig. 2g ), whereas fatty acid oxidation was slightly lower (Supplementary Fig. 2h ). These data indicate that liver and skeletal muscle malonyl-CoA content and fatty acid metabolism are sensitive to the regulatory phosphorylation of Acc1 at Ser79 and Acc2 at Ser212.
We examined the phenotype of AccDKI mice fed a standard chow diet. Growth curves (data not shown) and adiposity were similar (Fig. 1g) , but liver ( Fig. 1h) and skeletal muscle ( Supplementary  Fig. 2i ) diacylglycerol (DAG) and triacylglycerol (TAG) levels were elevated in AccDKI compared to WT mice. There were no differences in ceramide content in either tissue (data not shown). Elevated hepatic lipid content in AccDKI mice was associated with clinical signs of NAFLD, including an increased level of fibrosis (Fig. 1i) and a slightly elevated serum ratio of alanine aminotransferase to aspartate aminotransferase (Supplementary Fig. 2j ) compared to WT controls. Pathological accumulation of DAG has been shown to activate atypical isoforms of protein kinase C (Pkc) 15 , specifically Pkc-ε and Pkc-δ in liver 16 and Pkc-θ in skeletal muscle 17 , which have been shown to interfere with canonical insulin signaling. Consistent with this, AccDKI mice had greater amounts of membrane-associated (Fig. 1j) and phosphorylated Pkc-ε (Supplementary Fig. 3a ) in liver and Pkc-θ in skeletal muscle (Supplementary Fig. 3b ) compared to control animals, whereas amounts of membrane-associated Pkc-δ did not differ between AccDKI and WT mice (data not shown). These results demonstrate that Acc Ser79 and Ser212 phosphorylation play an essential part in preventing ectopic lipid accumulation independent of body mass or adiposity.
The storage of excess lipid in insulin-sensitive organs such as liver and skeletal muscle is strongly associated with insulin resistance 15, 18 . We found that AccDKI mice were hyperglycemic (Fig. 2a) , hyperinsulinemic (Fig. 2b) and also glucose (Fig. 2c) and insulin intolerant (Fig. 2d) compared to WT controls. Hyperinsulinemic-euglycemic clamp experiments (Supplementary Fig. 3c ) revealed that AccDKI mice had a lower glucose infusion rate (GIR) (Fig. 2e) , a lower glucose disposal rate (GDR) (Fig. 2e) , elevated hepatic glucose production (HGP) (Fig. 2f) and a lower suppression of HGP by insulin (Fig. 2g) compared to WT controls. Further, livers from AccDKI mice had reduced Akt kinase (Ser473) and FoxO1 transcription factor (Ser253) phosphorylation (Fig. 2h,i ) and higher gluconeogenic gene expression at the completion of the clamp (Fig. 2j) compared to WT controls. In addition, we found that c-Jun N-terminal kinase (Jnk), which also inhibits canonical insulin signaling 19 , was unchanged in livers from chow-fed AccDKI mice (Supplementary Fig. 3d ). We observed a trend toward decreased 2-deoxyglucose (2-DG) uptake into skeletal muscle of AccDKI mice during the clamp (Supplementary Fig. 3e ) and a marked reduction in muscle Akt (Ser473) and FoxO1 (Ser253) phosphorylation (Supplementary Fig. 3f,g ) at the completion of the clamp compared to WT control mice. Furthermore, insulin resistance in AccDKI mice was independent of changes in liver or adipose tissue macrophage accumulation, inflammatory cytokine gene expression or protein content ( Supplementary Fig. 4a -c) or differences in circulating free fatty acids ( Supplementary Fig. 4d ). These results indicate that Acc phosphorylation is required to maintain insulin sensitivity in lean healthy mice. Notably, mice with complete deletions of Ampk isoforms in skeletal muscle 20 or liver 21 have normal lipid levels and insulin sensitivity, suggesting that in these models, there may be alterations in compensatory pathways that are important for controlling fatty acid metabolism. Over 120 million people are prescribed metformin for the management of type 2 diabetes 22 . As metformin indirectly activates Ampk, it was initially thought that Ampk mediates metformin's therapeutic actions 23 . However, acute inhibition of gluconeogenesis by metformin is independent of Ampk 21 and involves inhibition of glucagon signaling through protein kinase A (Pka) 24 . Nevertheless, the ability of metformin to lower blood glucose in obese individuals with type 2 diabetes involves chronic enhancement in insulin sensitivity [25] [26] [27] [28] [29] . We found that acute metformin treatment activated hepatic Ampk in both genotypes, but this was only associated with increased Acc phosphorylation ( Fig. 3a) and reduced malonyl-CoA levels ( Fig. 3b) in WT mice. Metformin reduced de novo lipogenesis in hepatocytes from WT mice, and this suppressive effect was equivalent to that caused by Ampk-β1-specific activation using A-769662 (ref. 30) (Fig. 3c) . Notably, the metformininduced inhibition of hepatic lipogenesis seen upon Ampk activation was entirely mediated by Ampk phosphorylation of Acc, as metformin and A-769662 were ineffective at suppressing lipogenesis in AccDKI or Ampk-β1-deficient hepatocytes (Fig. 3c) . However, unlike A-769662, metformin did not increase fatty acid oxidation in either genotype (Supplementary Fig. 4e ). These data demonstrate that the effects of metformin on lipogenesis are specific to Ampk and indicate that although Ampk may inhibit multiple targets in this pathway, including sterol regulatory element binding protein-1c (ref. 31 ) and expression of fatty acid synthase 32 , the primary regulation of lipogenesis is dependent on the phosphorylation of both Acc1 and Acc2. In contrast, lipogenesis was inhibited by metformin in hepatocytes from both WT and Acc1 knock-in (Acc1KI) mice ( Supplementary  Fig. 4f) , and in vivo, a lipid-lowering effect was demonstrated in highfat diet (HFD)-fed WT and Acc1KI animals treated with metformin ( Supplementary Fig. 4g ).
In humans, therapeutic doses of metformin (0.5-3 g per day) 27 result in plasma concentrations ranging from 10 to 25 µM (refs. 33, 34) . In rodents, the administration of 50 mg per kg body weight of metformin has been shown to elicit plasma concentrations of 29 µM (ref. 35) . We therefore treated HFD-fed WT and AccDKI mice with a daily dose of metformin at 50 mg per kg body weight for 6 weeks. In contrast to chow-fed mice, HFD-fed AccDKI mice showed no differences in any metabolic parameters compared to HFD-fed WT animals ( Fig. 3 and Supplementary Figs. 5-7) . This indicates that diet-induced obesity overwhelms the effect of signaling by endogenous Ampk to Acc unless an external Ampk stimulus is provided.
Metformin has been shown to have positive effects on fatty liver in some but not all clinical trials 25 . However, rodent studies with metformin have demonstrated a clear lipid-lowering effect 23, 30 , which suggests the need for more robust analyses or the development of more reliable biomarkers in human studies 25, 36 . Notably, in vivo Data are expressed as means ± s.e.m. *P < 0.05 and **P < 0.01 relative to WT, as determined by Student's t-test. Relative gene expression was normalized to Actb, and duplicate gels were run for quantification of total Akt and Gapdh.
npg lipogenesis was similar between HFD-fed WT and AccDKI mice (Fig. 3d) , and an acute dose of metformin (50 mg per kg body weight) suppressed lipogenesis in vivo by ~35% in WT livers yet was completely ineffective in AccDKI mice (Fig. 3d) . We next assessed the metabolic effects of chronic metformin treatment and found that, independent of change in weight or adiposity ( Supplementary  Fig. 5c ), hepatic lipid content was reduced in WT mice, an effect completely absent in AccDKI mice (Fig. 3e-g ). Reductions in hepatic DAG were accompanied by decreased membrane-associated ( Fig. 3h) and Ser729-phosphorylated Pkc-ε (Supplementary Fig. 5d ) and lower Jnk activation (Supplementary Fig. 5e ) in metformintreated WT but not AccDKI mice. In addition to reducing hepatic lipid content, chronic metformin treatment of HFD-fed WT but not AccDKI mice was associated with lowered fasting blood glucose (Fig. 4a) , a trend toward lowered serum insulin levels (Supplementary Fig. 5f ) and improved glucose tolerance (Supplementary Fig. 5g ) and insulin sensitivity (Fig. 4b) . Metformin-induced suppression of cAMP and glucagon-dependent hepatic glucose output is independent of Ampk 21, 24 , and in hepatocytes from WT, AccDKI and Ampk-β1-deficient mice, metformin was effective at suppressing cAMP-stimulated glucose production (Supplementary Fig. 5h) . Metformin was also able to acutely lower circulating glucose levels in both chow-fed and obese HFD-fed WT and AccDKI mice, as shown by metformin tolerance tests (200 mg per kg body weight 37 ) (Supplementary Fig. 5i) . However, at the dose that was used for our chronic treatments (50 mg per kg body weight), glucose levels were unaltered (Supplementary Fig. 5j) , strongly suggesting that metabolic differences following chronic metformin treatment between AccDKI and WT mice were primarily the result of differential regulation of insulin sensitivity rather than acute effects on glucose lowering.
In hyperinsulinemic-euglycemic clamp experiments, chronic metformin treatment improved GDR (Supplementary Fig. 6a) and skeletal muscle 2-DG uptake in both WT and AccDKI mice (Supplementary Fig. 6b,c) . This is consistent with an AmpkPkc-dependent pathway controlling metformin-induced skeletal muscle glucose uptake 38 . In contrast, chronic metformin treatment increased GIR (Supplementary Fig. 6d-g ), decreased HGP (Fig. 4c) and increased suppression of HGP by insulin (Fig. 4d) in WT but not AccDKI mice. Enhanced Akt (Ser473) and FoxO1 (Ser253) phosphorylation (Supplementary Fig. 7a,b) and reduced gluconeogenic gene expression (Supplementary Fig. 7c ) at the completion of the clamp in WT but not in AccDKI mice provides further evidence of metformin-induced improvements in hepatic insulin sensitivity. We demonstrated that metformin improved insulin sensitivity in a liver cell-autonomous manner in a cellular model of palmitate-induced insulin resistance. In particular, hepatocytes made insulin resistant by chronic treatment (18 h) with the saturated fatty acid palmitate were treated with metformin, which improved insulin-stimulated phosphorylation of Akt Ser473 and FoxO1 Ser253 (Fig. 4e) , insulin-induced suppression of gluconeogenic gene expression (Fig. 4f) and insulin-induced suppression of hepatic glucose production ( Fig. 4g) in hepatocytes from WT but not AccDKI mice. Notably, the beneficial metabolic effects of specific Ampk activation by A-769662 were completely abrogated in AccDKI hepatocytes and in vivo (Supplementary Fig. 8a-d) , which corroborates the fundamental importance of Ampk-Acc signaling for hepatic lipid metabolism and insulin sensitivity.
Metformin remains the primary therapeutic option for the treatment of type 2 diabetes, although the precise mechanisms by which it confers its beneficial effects are incompletely understood. Glucagondriven hepatic gluconeogenesis maintains glycemia during states of fasting, and this is poorly regulated in patients with type 2 diabetes. Recently, it has been shown that metformin counters this program by inhibiting glucagon-stimulated cAMP production, thereby reducing Pka activity and glucagon-stimulated glucose output from . (e-g) Representative staining (H&E) of hepatic sections (e) (scale bars, 100 µm) and determination of hepatic DAG (f) and TAG (g) (n = 7 WT and n = 8 AccDKI) from WT and AccDKI mice fed a HFD for 12 weeks, with or without concurrent metformin (Met) (50 mg per kg body weight per day) starting after 6 weeks of HFD (HFD Met). (h) Activation of hepatic Pkc-ε, shown as the ratio of membrane to cytosolic expression and expressed relative to chow WT control (n = 7) (cytosol normalized to Gapdh and membrane normalized to caveolin-1 (Cav-1); blots shown are from duplicate gels). Data are expressed as means ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to WT control and # P < 0.05 and ### P < 0.01 are differences between treatment, as calculated by two-way ANOVA and Bonferonni post hoc test.
npg l e t t e r s nature medicine VOLUME 19 | NUMBER 12 | DECEMBER 2013 1 6 5 3 the liver 24 . We confirmed that this mechanism also operates in both WT and AccDKI mice in response to high concentrations of metformin (Supplementary Fig. 8e ). An important distinction between this previous work 24 and our current study is their focus on the fasting, or glucagon-specific, actions of metformin, which occur in the absence of insulin stimulation. The ability of insulin to suppress hepatic gluconeogenesis and to promote the efficient uptake of glucose in the periphery is fundamental and dramatically decreased in insulin resistance and type 2 diabetes. The insulin-sensitizing effects of metformin have been well documented 25, 28, 29 , but mechanistic insight has been lacking. Our data provide evidence that in the setting of obesity and insulin resistance, chronic metformin treatment (at a clinical dose) reduces hepatic lipogenesis and lipid accumulation by activation of Ampk and consequent inhibition of both Acc1 and Acc2. This lipid-lowering effect then alleviates obesity-induced insulin resistance. Notwithstanding metformin inhibition of glucagon-dependent gluconeogenesis, we provide evidence for a parallel mechanism, whereby chronic metformin treatment increases insulin sensitivity through alterations in hepatic lipid homeostasis (Fig. 4h) .
Since the initial discovery that Ampk directly phosphorylates Acc1, the site-specific phosphorylation of Acc1 and Acc2 has been used as a surrogate marker for Ampk signaling in hundreds of studies. Currently, more than 30 other substrates of Ampk have been identified in multiple metabolic pathways. Through genetic targeting of Acc1 Ser79 and Acc2 Ser212 and the generation of knock-in mice, we show that phosphorylation and inhibition of these two Ampk substrates is critical for maintaining lipid metabolism and insulin sensitivity. Moreover, Acc phosphorylation by Ampk also underpins the insulin-sensitizing effects of metformin.
MeThoDS
Methods and any associated references are available in the online version of the paper. (h) Schematic representation of metformin's therapeutic effects on hepatic action during differential nutrient and hormonal programs. Oct1, organic cation transporter 1; GR, glucagon receptor; Ac, adenylate cyclase; DNL, de novo lipogenesis; Creb, cAMP response element-binding protein; Pfkfb1, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1; IR, insulin receptor. Data are expressed as means ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 represent differences between genotype and # P < 0.05, ## P < 0.01 and ### P < 0.001 are differences between treatment, as calculated by two-way ANOVA and Bonferonni post hoc test. 2 was trapped in 400 µl of 1 M benzethonium hydroxide and radioactivity determined. Cellular lipids were extracted after a PBS wash, and radioactivity of the acid soluble intermediates was determined.
Total oxidation was then calculated as a function of both [ 14 C]CO 2 -produced and incomplete oxidation products. For insulin signaling experiments in hepatocytes, cells were incubated in the presence or absence of 0.5 mM palmitate (conjugated to 2% BSA) and 0.5 mM metformin for 18 h (with 0.1% FBS). Cells were then stimulated with 10 nM insulin; gluconeogenic gene expression was assessed after 6 h of insulin treatment, and insulin signaling was assessed after 5 min of insulin stimulation. Hepatic glucose production was determined as previously described 22 . Briefly, cells were cultured as above in the presence of 100 nM dexamethasone. Cells were washed once with PBS and incubated in glucose-free DMEM (100 nM dexamethasone, 10 mM lactate and 1 mM pyruvate) with or without Bt 2 -cAMP (100 µM) and with or without indicated doses of metformin or A-769662. For chronic treatments, palmitate-, metformin-and A-769662-supplemented medium was removed after 18 h, cells were washed and glucose-free DMEM was added to measure glucose output in the presence or absence of insulin (10 nM). Glucose in the medium after 4 h was assessed by glucose oxidase kit.
Statistical analyses.
All results shown are mean ± s.e.m. Results were analyzed using a two-tailed Student's t-test or two-way ANOVA, where appropriate, using GraphPad Prism software. A Bonferonni post hoc test was used to test for significant differences revealed by the ANOVA. Significance was accepted at P ≤ 0.05.
